Erasca, Inc. is a high-risk Pharmaceuticals company based in the United States specializing in precision oncology. Focused on developing therapies for patients with RAS/MAPK pathway-driven cancers, Erasca's pipeline includes innovative treatments targeting various tumors. With an ESG score of 33.2, Erasca is dedicated to sustainability and governance in the pharmaceutical industry. Discover more about Erasca's cutting-edge research and groundbreaking solutions for cancer patients.